13856 research outputs found
Sort by
抗-乙型澱粉樣蛋白抗體及其用途
No full text[[abstract]]一种分离的抗体，其结构包含：轻链CDR1，轻链CDR2，重链CDR1，重链CDR2，以及重链CDR3，所述抗体对Aβ1‑42或一N端修饰型Aβ1‑42都具有特异性结合能力。该抗体可用于治疗AD和早期检测脑Aβ含量。N端修饰的焦麸氨酸Aβ(pE‑Aβ3‑42)非常易于聚集，并且对Aβ斑块
Heterocyclic compounds and use thereof
No full text[[abstract]]Heterocyclic compounds of Formula (I) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds. Further disclosed are methods of using one of the heterocyclic compounds for mobilizing hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation, and for treating tissue injury, cancer, inflammatory disease, and autoimmune disease
杂环化合物及其用途
No full text[[abstract]]本文提供一种式(I)的杂环化合物，也公开了一种包含该杂环化合物之一的药物组合物。更进一步公开了使用该杂环化合物之一用于驱动造血干细胞和内皮前驱细胞进入周边循环的方法，以及用于治疗组织伤害、癌症、发炎性疾病、和自体免疫疾病的方法
Dipicolylamine derivatives and their pharmaceutical uses
No full text[[abstract]]Dipicolylamine compounds of Formula (I) set forth herein. Also disclosed are pharmaceutical compositions containing metal ions and these compounds. Further disclosed is a method for treating a condition associated with cells containing inside-out phosphatidylserine, with these compounds
ジピコリルアミン誘導体及びそれらの薬学的使用
No full text[[abstract]]Dipicolylamine compounds of Formula (I) set forth herein. Also disclosed are pharmaceutical compositions containing metal ions and these compounds. Further disclosed is a method for treating a condition associated with cells containing inside-out phosphatidylserine, with these compounds
吡唑类化合物
No full text[[abstract]]本发明公开了如化学式(I)所示的吡唑类化合物，其可用于治疗周边大麻素1受体介导的疾病，此外，本发明亦公开了关于该些化合物的医药组合物以及使用方法
複素環式化合物及びその使用
No full text[[abstract]]Heterocyclic compounds of Formula (I) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation. Further provided are methods for treating tissue injury, cancer, inflammatory disease, and autoimmune disease with the heterocyclic compounds
Composto de fórmula (i) e composição farmacêutica
No full text[[abstract]]Heterocyclic compounds of Formula (I) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation. Further provided are methods for treating tissue injury, cancer, inflammatory disease, and autoimmune disease with the heterocyclic compounds
Assessing mobility and fall risks in Taiwan's older adult population: A longitudinal study
No full text[[abstract]]Mobility difficulties impact older adults’ health significantly, leading to adverse outcomes and loss of independence. In Taiwan, 21% of community-dwelling older adults report falls, and over half have a fear of falling, highlighting the importance of identifying individuals at risk. This study aimed to explore mobility changes and repeated falls in Taiwan’s rural areas, where the older population exceeds 24%. A longitudinal study was conducted annually from 2022 to 2023, focusing on physical ability and gait assessments in community-dwelling older adults (65+) who were able to walk (n=250). We used linear mixed-effects regression models and logit models to examine whether personal characteristics are associated with changes in mobility and falls. The findings showed no significant differences in falls and walking performance at the 1-year follow-up after confounder adjustments. However, individuals living in buildings without elevators, using walking devices with cognitive impairment and exhibiting poorer gait performance such as slower gait speed, peak angle velocity at swing phase and toe clearance were more likely to experience repeated falls. Furthermore, about 14.78% of participants who were independently walking at baseline began using a walking device by 2023, indicating a transition to new walking dependence (NWD). The NWD group tended to have a higher number of chronic illnesses, repeated falls and slower walking speed. This study highlights the need to consider environmental and gait characteristics in addressing the mobility dependence and fall risks. Interventions to prevent falls and facilitate the adaptation to walking assistive devices could help manage mobility decline among older adults
The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer
No full text[[abstract]]In our previous phase II T1219 trial for advanced biliary tract cancer (ABTC), the combination of nivolumab with modified gemcitabine and S-1 exhibited promising efficacy, while the programmed-death-ligand-1 (PD-L1) expression did not predict chemoimmunotherapy efficacy. Lymphocyte-activation-gene-3 (LAG-3), a negative immune checkpoint, is frequently co-expressed with PD-L1. This study assessed the predictive value of LAG-3 expression in ABTC patients who received chemoimmunotherapy. We analyzed 44 formalin-fixed ABTC samples using immunohistochemical staining for PD-L1 and LAG-3 and correlated them with the clinical efficacy of chemoimmunotherapy. Digital spatial profiling was conducted in selected regions of interest to examine immune cell infiltration and checkpoint expression in six cases. Three public BTC datasets were used for analysis: TCGA-CHOL, GSE32225, and GSE132305. LAG-3 positivity was observed in 38.6% of the ABTC samples and was significantly correlated with PD-L1 positivity (P = 10%, respectively; P = 0.018) and a deeper therapeutic response (20.1%, 38.6%, and 57.6% for the same respective groups; P = 0.04). LAG-3 expression is positively correlated with the expression of numerous immune checkpoints. Enrichment of CD8(+) T cells was observed in LAG-3-positive BTC, indicating that LAG-3 expression may serve as a biomarker for identifying immune-inflamed tumors and predicting the therapeutic response to chemoimmunotherapy in ABTC